HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
Clinical trials for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) explained in plain language.
Never miss a new study
Get alerted when new HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) trials appear
Sign up with your email to follow new studies for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibiotic YK-1169 takes on deadly hospital pneumonia
Disease control Not yet recruitingThis Phase 3 trial tests a new antibiotic called YK-1169 against a standard treatment (ceftazidime-avibactam) for adults with pneumonia caught in the hospital or from a ventilator. About 590 participants will receive either drug for 7-14 days. The main goal is to see if YK-1169 l…
Matched conditions: HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
Phase: PHASE3 • Sponsor: Nanjing Yoko Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New weapon against superbug pneumonia and blood infections
Disease control Not yet recruitingThis study tests a new antibiotic combination (BV100 plus other drugs) against hard-to-treat infections like pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. About 120 adults in the hospital will receive either the new combo or the best…
Matched conditions: HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
Phase: PHASE2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC